Table 3 Univariate and multivariate analysis of TSC22D3 expression and clinical parameters on OS of 173 adult AML patients from the “TCGA-AML NEJM 2013” dataset of the cBioportal database

Age

173

 < 0.001

  ≤ 60

97

Reference

Reference

  > 60

76

3.131 (2.147–4.565)

 < 0.001

2.047 (1.244–3.368)

Sex

173

0.770

 Male

92

Reference

 Female

81

1.056 (0.731–1.526)

0.770

Race

136

0.628

 White

128

Reference

 Black

8

0.806 (0.328–1.983)

0.639

WBC count (× 10^9/L)

173

0.291

  ≤ 20

91

Reference

  > 20

82

1.219 (0.844–1.761)

0.290

PB blast percentage

170

0.577

  < 20

68

Reference

  ≥ 20

102

1.112 (0.764–1.620)

0.579

Bone marrow blast percentage

173

0.451

  ≤ 70%

78

Reference

  > 70%

95

1.153 (0.796–1.669)

0.452

FAB

171

0.067

 M0

16

Reference

 M1

44

0.989 (0.495–1.974)

0.975

 M2

38

0.909 (0.447–1.848)

0.792

 M3

16

0.307 (0.106–0.887)

0.029

 M4

34

1.028 (0.506–2.090)

0.939

 M5

18

1.136 (0.501–2.577)

0.760

 M6

2

2.635 (0.578–12.017)

0.211

 M7

3

2.364 (0.654–8.543)

0.189

Cytogenetics

171

0.005

 Normal

80

Reference

 Complex

22

1.857 (1.088–3.171)

0.023

1.548 (0.716–3.346)

 t(15;17)

15

0.360 (0.144–0.903)

0.029

0.400 (0.150–1.069)

 t(8;21)

7

0.485 (0.152–1.553)

0.223

0.626 (0.184–2.130)

 t(9;22)

3

2.266 (0.547–9.393)

0.259

5.015 (1.117–22.510)

 inv(16)

10

0.308 (0.096–0.986)

0.047

0.373 (0.114–1.225)

 t(11q23)

4

1.494 (0.466–4.791)

0.500

2.169 (0.659–7.141)

  + 8

8

1.231 (0.529–2.866)

0.630

1.303 (0.487–3.486)

  − 7

4

1.672 (0.522–5.362)

0.387

2.253 (0.692–7.333)

  + 21

3

1.907(0.594–6.120)

0.278

3.493 (1.053–11.585)

 Other

15

1.328(0.710–2.483)

0.375

1.920 (1.007–3.660)

FLT3 mutation

173

0.180

 Negative

124

Reference

 Positive

49

1.325 (0.885–1.984)

0.171

NPM1 mutation

173

0.490

 Negative

125

Reference

 Positive

48

1.155 (0.770–1.732)

0.486

DNMT3A mutation

173

0.038

 Negative

131

Reference

Reference

 Positive

42

1.571 (1.040–2.373)

0.032

1.675 (1.060–2.647)

IDH2 mutation

173

0.915

 Negative

156

Reference

 Positive

17

1.033 (0.567–1.884)

0.915

IDH1 mutation

173

0.304

 Negative

157

Reference

 Positive

16

0.711 (0.360–1.406)

0.327

TET2 mutation

173

0.991

 Negative

158

Reference

 Positive

15

0.996 (0.521–1.907)

0.991

TP53 mutation

173

 < 0.001

 Negative

159

Reference

Reference

 Positive

14

4.100 (2.291–7.339)

 < 0.001

2.691 (1.145–6.323)

CEBPA mutation

173

0.829

 Negative

160

Reference

 Positive

13

0.928 (0.470–1.834)

0.831

Treatment type

173

0.001

 Chemotherapy

100

Reference

Reference

 Transplant

73

0.519 (0.355–0.761)

0.001

0.466 (0.272–0.797)

TSC22D3 expression

173

0.042

 Low

86

Reference

Reference

 High

87

1.466 (1.012–2.122)

0.043

1.546 (1.031–2.320)